CureVac (CVAC.US) loses more than 30% today after a German court quashed a company's patent. As Reuters analysis reports, the patent in question is one of several intellectual property titles that CureVac claims were infringed in ongoing legal proceedings. The patent was also the basis of a patent violation lawsuit by CureVac against its market rival and mRNA vaccines producer, BioNTech (BNTX.US), in a blow to CureVac's claims for a share in billions of euros in COVID-19 vaccine revenues. As presiding judge in Germany's patent court, said in his ruling after a hearing, the patent is now invalid for the Germany territory. Biontech's shares are up 2% today. CureVac'smRNA-based COVID-19 vaccine didn't bring any significant cash from sales. At the same time, BioNTech / Pfizer collaboration made more than $40 billion in combined vaccines sales in 2021 and 2022.
Source: xStation5
ข่าวเด่นวันนี้ 19 มกราคม
ผู้นำอันดับหนึ่งในกลุ่ม: ผลประกอบการ BlackRock สะท้อนภาพตลาดอย่างไร?
US OPEN: ผลประกอบการธนาคารและกองทุนหนุนให้มูลค่าหุ้นยังคงน่าสนใจ
เงินทุนไหลเข้าหุ้นเทคโนโลยียุโรป 💸🔎
